2026-10-25
Does not pass
Inventiva does not pass the ethical screen. The binding factor is interest/revenue 65.7%.
NAS100 29,813 +0.55%
S&P 7,744 +0.28%
GOLD $4,071 −0.10%
BTC $79,851 −1.18%
VIX 16.91 −3.48%
latest tape · as of 02:01 UTC
The Screen · Healthcare
Inventiva S.A.
IVA · Nasdaq · USD · Market cap $678M
FAIL · Does not pass the screen3.71 USD
Price as of 23 Oct 2026Daily close, not a live quoteLast reviewed 6 days ago
Screened 2026-10-23 · the tape above runs as of 02:01 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price3.71 USD at the 23 Oct 2026 close
- Ethical screenDoes not pass
- OptionsOpen interest leans to puts (put/call 16.73)
- Last reviewed23 Oct 2026 (6 days ago)
A summary of the dated readings below, not a live quote and not advice.
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 3.71 against the desk's fair-value range, base estimate 9.56, over the last year.
- Trend Markup
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 16.73, read 2026-10-18
- Ethical does not pass the values gate
Price3.71 USD
Fair value9.56
Our investment reviews on this name
2026-10-25Read Markup3.11+19.3% to today ✓Distribution gives way to Markup
2026-10-11Read Distribution3.26+13.8% to today Markdown gives way to Distribution
2026-10-02Read Markdown3.26+13.8% to today Accumulation gives way to Markdown after a 32% slide in 4 weeks
2026-09-02Read Accumulation4.76-22.1% to today Distribution gives way to Accumulation
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
The full research record, in depth, below
This name holds its markup label.
Inventiva S.A. holds its Markup at $3.71. The statistical read favours the sellers, held for 17 days.
| Phase | Markup |
| Quantitative state | The statistical read favours the sellers, held for 17 days |
| Price at the screen | $3.71 |
| Valuation | N/A trailing · -3.85 forward price to earnings |
| Values screen | FAIL |
| Beta | 1.00 |
Five Screens, Shown in Full
Does not pass. Interest/revenue 65.7%
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 21.84% | Below 33% | Interest-bearing debt is just 21.8% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 9.44% | Below 33% | Cash held in interest-bearing accounts and securities is 9.4% of assets, under the one-third limit. | Pass |
| Receivables | 0.00% | Below 49% | Money owed to the company is 0.0% of assets, under the 49% limit. | Pass |
| Revenue purity | 65.69% | Below 5% | 65.7% of revenue comes from non-compliant sources, over the 5% line. | Fail |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Falls Short, in Plain English
Inventiva does not pass the ethical screen. The binding factor is interest/revenue 65.7%.
Read as at 2026-10-28. It updates when the underlying figures move, and past reads are kept below.
2026-09-24
Clears
Inventiva clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 22%, inside the ~33% line, and almost none of its income is interest, so it passes.
Earlier reads, kept as written. The ethical profile is tracked over time, not overwritten.
Follow this verdict
Get an email when IVA's ethical verdict changes
Today IVA does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Fair value range in USD, drawn from the 2026-10-23 screen. The gold marker is the market price at the same screen. A 161.9% margin of safety to the base estimate.
Third-party analyst targets: 10 covering, consensus Strong Buy. The average target sits +277% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & ProjectionsWhere it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-23 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsCollapsing revenue rarely signals hidden value
A biotech firm that has just lost nine tenths of its revenue is not the usual picture of opportunity. Inventiva trades at half our own fair value estimate and carries a forward multiple that reflects deep losses, yet our screen gives it a flat opportunity rating despite the analyst chorus calling for a near threefold rise.
The business shows zero profit margins and negative earnings, so the apparent discount may simply mark peak risk rather than a bargain. Currency moves or trial setbacks could wipe out the remaining cash runway long before any product reaches market.
Ethical screens clear the name, but the combination of evaporating sales and heavy reliance on future clinical wins leaves too little margin for error. Analysis, not advice.
| Forward P/E | -3.8x |
| EPS, trailing | -0.62 |
| EPS, forward | -0.75 |
| Revenue growth | -76.7%revenue is shrinking |
| Profit margin | 0.0%currently unprofitable |
| Return on equity | -989.1%not currently earning a positive return on equity |
| FCF yield | -17.13% |
| Debt to equity | 2.35heavy leverage: higher risk if revenue softens |
| Current ratio | 3.81comfortably covers its short-term bills |
| Beta | 1.00steadier than the market |
| Short interest, float | 0.04% |
| 52-week range | 2.82 - 7.98 |
| Market cap | $678M |
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeIVA trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
2026-10-25
Markup · changed $3.11
+0.0% Entry 9
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (12 analysts) rates it strong buy, with a mean price target of $16.
2026-10-18
Distribution $3.11
-4.6% Entry 8
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 4.6% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 3% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (12 analysts) rates it strong buy, with a mean price target of $16.
2026-10-11
Distribution · changed $3.26
+0.0% Entry 7
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 3% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (12 analysts) rates it strong buy, with a mean price target of $16.
2026-10-02
Markdown · changed $3.26
-31.5% Entry 6
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 31.5% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 3% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (12 analysts) rates it strong buy, with a mean price target of $16.
2026-09-02
Accumulation · changed $4.76
+3.0% Entry 5
The framework has shifted from distribution to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 3.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 3% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (12 analysts) rates it strong buy, with a mean price target of $16.
2026-08-02
Distribution · changed $4.62
+14.6% Entry 4
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 14.6% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 3% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (12 analysts) rates it strong buy, with a mean price target of $16.
2026-07-18
Markdown $4.03
+0.0% Entry 3
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 3% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (12 analysts) rates it strong buy, with a mean price target of $16.
2026-07-03
Markdown $4.03
+0.0% Entry 2
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02
Markdown $4.03
Entry 1
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- 3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead Yahoo Finance · 19d ago
- Inventiva to Present Scientific Abstracts at AASLD The Liver Meeting® 2026 Yahoo Finance · 22d ago
- Inventiva (IVA): How Much Is One Make-or-Break Readout Really Worth? Yahoo Finance · 24d ago
- Inventiva Eyes Q4 2026 Phase III MASH Data as Lanifibranor Nears Key Test Yahoo Finance · 25d ago
- European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading Yahoo Finance · 30d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
GMRSGMR Solutions Inc.
PHARPharming Group N.V.
BBOTBridgeBio Oncology Therapeutics Inc
ANNXAnnexon, Inc.
CADLCandel Therapeutics, Inc.
SGPSpyGlass Pharma Inc
Screened names in the same industry · explore each on its own page.
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 2026-09-25 | Ro Khanna | Democrat | sell | 1K–15K |
| 2026-09-25 | Ro Khanna | Democrat | sell | 1K–15K |
| 2026-09-11 | Ro Khanna | Democrat | sell | 1K–15K |
| 2026-09-11 | Ro Khanna | Democrat | sell | 1K–15K |
| 2026-08-28 | Michael McCaul | Republican | buy | 500K–1M |
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $5.80 | -34.7% | · | $653 | -34.7% |
| 2 months | $5.26 | -28.0% | · | $721 | -28.0% |
| 3 months | $6.17 | -38.6% | · | $614 | -38.6% |
| 6 months | $4.49 | -15.6% | · | $844 | -15.6% |
| 1 year | $3.65 | +3.9% | · | $1,039 | +3.9% |
| 2 years | $3.15 | +20.3% | · | $1,203 | +20.3% |
| 3 years | $3.52 | +7.7% | · | $1,077 | +7.7% |
| 5 years | $15.67 | -75.8% | · | $242 | -75.8% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever IVA does next, these words stay.
Membership
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.